Earlier this year, the FDA approved 2 new indications for Aquaflor. According to Merck, the supplemental approval increased ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck’s Animal health and vaccine products are core growth drivers. It has a strong cancer pipeline, including Keytruda.

Despite challenges in GARDASIL sales, Merck & Co Inc (MRK) reports robust growth in KEYTRUDA and new product launches, ...

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange ...

Various veterinary businesses and organizations recently announced new promotions and appointments. The following individuals ...

Dow has been struggling to grow for several quarters. Keytruda now makes up close to half of Merck's revenue. As you can see ...

With a market cap of $258 billion, Merck & Co., Inc. (MRK) is a global healthcare company, operating in the pharmaceutical and animal health sectors. Based in Rahway, New Jersey, Merck develops ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...

Merck & Co., Inc.'s Q3 earnings report is anticipated ... falling owing to the patent expirations of Januvia and Janumet. Animal Health revenues also fell by ~2%. Despite the approval of Winrevair ...